| Filed On | Filing |
|---|---|
| 16 Jul 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +4 more
1.1 Registered Office. The registered office of the corporation in the State of Delaware shall be 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. |
| 08 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 30 Jun 2026 |
8-K: Other Events
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses |
| 23 Jun 2026 |
8-K: Other Events
As previously announced, on May 6, 2026, Catalyst Pharmaceuticals, Inc. (“Catalyst”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Angelini Pharma S.p.A., an Italian Società per azioni (“Angelini Pharma”), an... |
| 11 May 2026 |
8-K: Other Events
Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® |
| 07 May 2026 |
8-K: Entry into a Material Definitive Agreement; Amendments to Articles/Bylaws; Change in Fiscal Year +2 more
Form of Certificate of Incorporation of the Surviving Corporation |
| 18 Mar 2026 |
8-K: Other Events
On March 18, 2026, the District Court for the District of New Jersey filed an order delaying the start of the bench trial between the Company and Hetero USA, Inc. from March 23, 2026 until May 18, 2026. The bench trial relates to the val... |
| 25 Feb 2026 |
8-K: Other Events
Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
NASDAQ: CPRX Improving the Lives of Patients Living with Rare Diseases January 2026 Exhibit 99.1 |
| 05 Nov 2025 |
8-K: Other Events
Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® |
| 01 Oct 2025 |
8-K: Other Events
CORAL GABLES, Fla., October 1, 2025 - Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for peopl... |
| 25 Aug 2025 |
8-K: Other Events
CORAL GABLES, Fla., August 25, 2025- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patie... |
| 07 Aug 2025 |
8-K: Other Events
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC) |
| 06 Aug 2025 |
8-K: Other Events
Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth |
| 04 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
CORAL GABLES, Fla. – Aug. 4, 2025 – Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. |
| 02 Jun 2025 |
8-K: Other Events
Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career |
| 23 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
| 07 May 2025 |
8-K: Other Events
Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook |
| 09 Apr 2025 |
8-K: Other Events
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals |
| 26 Feb 2025 |
8-K: Other Events
Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth |
Loading...